 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12345678910111213...203204» |
- Rinvoq (upadacitinib) / AbbVie
CLINICAL AND ULTRASONOGRAPHIC REMISSION IN BIO-NA () - May 29, 2024 - Abstract #EULAR2024EULAR_3443;
A 24-weeks upadacitinib treatment led to complete remission in a high percentage of enrolled patients. The only baseline parameter associated with a higher chance of reaching complete remission at multivariate analysis was being bio-na
- Olumiant (baricitinib) / Eli Lilly
BARICITINIB IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 60 PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_3424;
The JAKi approved by the Food and Drugs Administration (FDA) and the European Medicines Agency (EMA) for the treatment of RA are baricitinib (BARI), tofacitinib, upadacitinib and filgotinib...All patients had received disease-modifying antirheumatic drugs (DMARDs) before BARI [methotrexate (52; 87%), leflunomide (41; 68%), sulfasalazine (18; 30%), abatacept (38; 63%), tocilizumab (24; 40%), adalimumab (18; 30%) and rituximab (15; 20%)]... BARI might be effective and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in ABA and/or RTX refractory patients.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Actemra SC (tocilizumab SC) / Roche, Halozyme
GENERAL SYMPTOMS AT TAKAYASU ARTERITIS DIAGNOSIS AND THE NUMBER OF IMMUNOSUPPRESSIVE DRUGS ARE ASSOCIATED WITH THE USE OF BIOLOGICAL THERAPY DURING THE COURSE OF THE DISEASE () - May 29, 2024 - Abstract #EULAR2024EULAR_3363;
Regarding therapy, 64 (82.1%) patients received prednisone as the initial therapy and 46 (59%) required immunosuppressive drugs, including methotrexate, azathioprine, cyclophosphamide, mycophenolate, and cyclosporine A. Table 1...BT included adalimumab (n=9), infliximab (n=3) and iv/sc tocilizumab (n=18)... The presence of fever or constitutional syndrome along with the use of immunosuppressive drugs appears to be related with the need of BT.
- Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
DOES COMBINED ARTERITIS DAMAGE SCORE (CARDS) AT THE DIAGNOSIS OF TAKAYASU' ARTERITIS PREDICT THE NEED FOR BIOLOGIC THERAPY? () - May 29, 2024 - Abstract #EULAR2024EULAR_3354;
Combination of CARDS and WT as mCARDS reached highest sensitivity and spesificity, and all scores seems useful to predict prognosis. Replication of this findings in larger cohort is needed.
- FOLLOW-UP DATA ON DRUG-INDUCED LUPUS CASES DURING TNF-ALPHA INHIBITOR TREATMENT () - May 29, 2024 - Abstract #EULAR2024EULAR_3249;
In patients who develop positive ds-DNA during the use of TNF inhibitors and exhibit mild symptoms, close monitoring while continuing the TNF inhibitor appears to be safe. Larger-scale studies are needed to establish a diagnosis, treatment, and follow-up algorithm in this field.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
DRUG-INDUCED LUPUS: CLINICAL AND SEROLOGICAL FEATURES IN A TERTIARY HOSPITAL () - May 29, 2024 - Abstract #EULAR2024EULAR_3234;
Anti-TNF agents were the most common drugs related to DIL. ANA tended to decrease over time, but only become undetectable in a few patients.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
NO PREDICTIVE EFFECT OF OBESITY ON CLINICAL RESPONSE IN PATIENTS WITH RA AND SpA AFTER 3 YEARS OF BIOLOGIC DRUGS: A MULTICENTER STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3171;
Thus no personalized treatment strategy should be considered for obese patients. Specific studies using DEXA examining the direct impact of obesity, and, ideally, of fat mass, on the therapeutic response of recently licensed bDMARDs and tsDMARDs are required.
- Humira (adalimumab) / AbbVie
SWITCHING FROM boDMARD ETANERCEPT OR ADALIMUMAB TO THEIR BIOSIMILARS IN CLINICAL PRACTICE: FAILURE RATES AND ASSOCIATED FACTORS IN A PROSPECTIVE STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3042;
therapy, as our patients had a mean duration of treatment that was systematically longer than that reported in these studies. The presence of AEs, particularly ISRs, was independently associated with early and late failure of bsDMARD.
- Humira (adalimumab) / AbbVie
SWITCHING FROM TNF INHIBITORS TO TOFACITINIB AMONG PATIENTS WITH STABLE DISEASE DUE TO COST IMPLICATIONS: DIFFERENTIAL LOSS OF RESPONSE IN MAJORITY OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES () - May 29, 2024 - Abstract #EULAR2024EULAR_3041;
There is paucity of data as regards switching therapy among patients with adequate disease control. Our prospective study shows that majority of patients have relapse of their inflammatory arthritis, and it was significantly higher among patients with AS, with 70% of patients having relapse of their disease.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
THE INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS WITH SPONDYLOARTHRITIS UNDER BIOTHERAPY IN THE MOROCCAN REGISTRY OF BIOTHERAPY: 3-YEAR FOLLOW-UP () - May 29, 2024 - Abstract #EULAR2024EULAR_2941;
The incidence of fungal infections in patients with spondyloarthritis is low, and remains similar to data in the literature. It seems to be related to disease activity and type of biologics.
- PATTERNS OF bDMARDs PRESCRIPTION IN SPONDYLOARTHRITIS AFTER FIRST TNFi FAILURE () - May 29, 2024 - Abstract #EULAR2024EULAR_2902;
Since 2017, novel targets have emerged, and IL-17i have showed efficacy in controlling disease activity. In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
HOW ARE PATIENT REPORTED OUTCOME MEASUREMENTS USED IN AXIAL SPONDYLOARTHRITIS? A QUALITATIVE STUDY WITH HEALTH CARE PROFESSIONALS AND PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2884;
People with axSpA would appreciate adequate information for their completion. Resistance to complete the questionnaires could be tackled with best practice examples on how to do it efficiently.
- FACTORS ASSOCIATED WITH CAUSE-SPECIFIC DISCONTINUATION OF LONG-TERM ANTI-TUMOR NECROSIS FACTOR AGENT USE IN PATIENTS WITH ANKYLOSING SPONDYLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_2880;
AS patients on their first anti-TNF treatment for at least two years demonstrated a favorable long-term treatment retention rate, with a 24.0% discontinuation rate over a 10.6-year overall survival period. The predictors for discontinuation varied by causes, underscoring the complexity of treatment response and the importance of personalized approaches to treatment management.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
DO MORE THERAPEUTIC OPTIONS LEAD TO A DECLINE IN THE RETENTION RATE OF BIOLOGICALS? A REAL-WORLD STUDY IN PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS () - May 29, 2024 - Abstract #EULAR2024EULAR_2867;
Although the 1-year retention rates in both PsA and SpA groups who received their first b/tsDMARD treatment between 2012-2016 were numerically slightly higher than in the groups who received their first dose of b/tsDMARD between 2017-2022, no statistically significant difference was found. Specific patient profiles for failure on the first bDMARD/tsDMARD therapy could not be identified.
- | Humira (adalimumab) / AbbVie
Journal: Prevalence of psoriasis and cutaneous mycoses: A descriptive study in Paran (Pubmed Central) - May 29, 2024
This is the first epidemiological study using SIA about the population affected by psoriasis, psoriatic arthritis, and cutaneous mycoses in a Brazilian state. We believe that these findings allow relevant contribution to science and public policies in Brazil.
- | Humira (adalimumab) / AbbVie
Journal: Autoimmune haemolytic anaemia, a delayed haematological complication of Adalimumab therapy. (Pubmed Central) - May 27, 2024
We believe that these findings allow relevant contribution to science and public policies in Brazil. No abstract available
- | Humira (adalimumab) / AbbVie
Observational data, Journal: Adalimumab (ADA) in Pediatric Non-infectious Uveitis: An Observational Study. (Pubmed Central) - May 27, 2024
- | Humira (adalimumab) / AbbVie
Journal: Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn's Disease: Secondary Analysis of the PYRAMID Registry. (Pubmed Central) - May 26, 2024
P=N/A
Patients with CD who respond to adalimumab have a lower risk of developing serious infections compared with nonresponders. These findings underscore that initiation of advanced therapy for CD may lower the risk of serious infections through effective disease control and avoidance of corticosteroids.
- || Review, Journal: Biologics for Psoriasis. (Pubmed Central) - May 26, 2024
IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-? inhibitors.
- Humira (adalimumab) / AbbVie
Observational data, Retrospective data, Journal: Natural language processing to identify and characterize spondyloarthritis in clinical practice. (Pubmed Central) - May 26, 2024
The application of NLP technology facilitated the characterisation of the SpA patient profile, including demographics, clinical features, comorbidities and treatments. This study supports the utility of NLP in enhancing the understanding of SpA and suggests its potential for improving patient management by extracting meaningful information from unstructured EHR data.
- | Humira (adalimumab) / AbbVie
Journal, Adherence: Optimising adalimumab administration to improve patient experience and treatment adherence in immune-mediated inflammatory diseases. (Pubmed Central) - May 25, 2024
This study supports the utility of NLP in enhancing the understanding of SpA and suggests its potential for improving patient management by extracting meaningful information from unstructured EHR data. No abstract available
- | Retrospective data, Journal, HEOR: Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data. (Pubmed Central) - May 24, 2024
No abstract available Further research should explore reasons leading to treatment discontinuation in order to support treatment choices for patients with moderate-to-severe psoriasis.
- || Review, Journal, Head-to-Head: Head-to-head studies on radiographic progression in axial spondyloarthritis (Pubmed Central) - May 21, 2024
Therefore, for the endpoint of radiological progression no difference could be shown in the inhibition of radiological progression between the mechanisms of action investigated. The comparative data for the endpoint of clinical efficacy showed that patients with bDMARDs showed a clearly better response to treatment than patients with NSAR or conventional synthetic DMARDs (csDMARD).
- ||| Journal, Adverse events, Real-world evidence, Real-world: Neurological disorders following the use of tumor necrosis factor-? inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. (Pubmed Central) - May 21, 2024
However, there were no signals among neurological AEs for golimumab. Neurological signals were detected for TNFi use, indicating that the risk of neurological AEs requires additional attention in clinical use of TNFis.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Standardizing steroid protocols for newly diagnosed inflammatory bowel disease patients: A quality improvement initiative. (Pubmed Central) - May 21, 2024
Neurological signals were detected for TNFi use, indicating that the risk of neurological AEs requires additional attention in clinical use of TNFis. Our experience illustrates that QI methodology can be used successfully to improve and standardize the steroid weaning process, leading to shortened steroid duration and without increased flares and hospitalizations.
- || PK/PD data, Review: Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review. (Pubmed Central) - May 20, 2024
Available information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy.
- || Humira (adalimumab) / AbbVie
Clinical, Journal, HEOR, Real-world evidence, Real-world: Comparative Effectiveness of Tofacitinib and Adalimumab in Axial Spondyloarthritis: A Real-World Clinical Context Multicenter Study. (Pubmed Central) - May 20, 2024
For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy. Tofacitinib showed comparable effectiveness with adalimumab in patients with AxSpA at the sixth month, despite lesser response in the initial months, with favorable ICER drug .
- Humira (adalimumab) / AbbVie
CROHN'S DISEASE STRICTURES RESPOND TO ADALIMUMAB DRUG TREATMENT. LONG TERM (4.5 YEARS) RESULTS OF THE STRIDENT RANDOMISED CONTROLLED TRIAL. (Hall A, Poster Hall - Walter E. Washington Convention Center) - May 18, 2024 - Abstract #DDW2024DDW_8592;
- | Journal: Rheumatoid factor titers, but not Fc fragments, may be strongly associated with drug survival of anti-TNF agents in patients with rheumatoid arthritis. (Pubmed Central) - May 17, 2024
Tofacitinib showed comparable effectiveness with adalimumab in patients with AxSpA at the sixth month, despite lesser response in the initial months, with favorable ICER drug . Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs.
- || Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Review, Journal: Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review. (Pubmed Central) - May 17, 2024
In head-to-head comparison with adalimumab, filgotinib 200 mg was non-inferior. Adverse effects alerts are marked by the elevated risk of infectious adverse effects with the exception of herpes zoster infection, which has a low incidence.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY (C9) - May 16, 2024 - Abstract #EULAR2024EULAR_2832;
In paediatric patients with JPsA and ERA, efficacy of IXE was demonstrated with an overall 88.9% JIA ACR30 response rate at W16. Safety findings were consistent with the known safety profile of IXE.
- Cosentyx (secukinumab) / Novartis
SECUKINUMAB VERSUS STANDARD-OF-CARE IN AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED OPEN-LABEL TRIAL FOR TREAT-TO-TARGET OUTCOMES (ASCALATE) (C8) - May 16, 2024 - Abstract #EULAR2024EULAR_2829;
Observations are consistent with TICOSPA trial [3]. AxSpA patient care was found to be close to T2T strategy in the participating expert centers.
- | Stelara (ustekinumab) / J&J
Journal: Disseminated Mycobacterial Infection With Reactive Polyarthritis (Poncet's Disease) During Immune-suppressive Treatment Including Ustekinumab for Pediatric Crohn's Disease. (Pubmed Central) - May 16, 2024
Disseminated MI should be considered and ruled out in these patients when presenting with pulmonary, extrapulmonary or unusual clinical manifestations, like PD. The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected.
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected. The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
- | Journal: Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - May 15, 2024
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA. Interruption of antipsoriatic oral and biologic therapies is generally not necessary for
- || Review, Journal: Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. (Pubmed Central) - May 12, 2024
Low doses, intermittent treatment may increase ADA formation. An appropriate biologic should be selected based on the ADA formation rate and course of treatment.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. (Pubmed Central) - May 11, 2024
P=N/A
Low drug concentrations at the end of the induction period predict loss of response by year 3 of treatment, suggesting higher drug concentrations during the first year of treatment, particularly during induction, might lead to better long-term outcomes. Anti-drug antibodies associated with undetectable drug concentrations of infliximab, but not adalimumab, can be predicted by carriage of HLA-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs.
- | Humira (adalimumab) / AbbVie
Journal: Investigation of long-term pressure on primary packaging materials and a biologic drug product for injection with a novel autoinjector concept. (Pubmed Central) - May 10, 2024
Anti-drug antibodies associated with undetectable drug concentrations of infliximab, but not adalimumab, can be predicted by carriage of HLA-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs. Lowest glass breaking pressures at 4922
- | Journal: Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. (Pubmed Central) - May 10, 2024
Lowest glass breaking pressures at 4922 Eleven clinical trials enrolling 5450 UC patients (infliximab
- | Entyvio (vedolizumab) / Takeda
Journal, HEOR, Real-world evidence, Real-world: Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence. (Pubmed Central) - May 8, 2024
Eleven clinical trials enrolling 5450 UC patients (infliximab This simulation model using real-world evidence indicates that positioning VDZ or ADA as the first biologic is likely to lead to improved long-term patient outcomes when compared to administering these treatments later or starting with IFX monotherapy.
- Humira (adalimumab) / AbbVie
Roadmap for the accelerated development and clinical translation of fluorescent tracers using adalimumab-680LT (Exhibit Hall D - Science Pavilion (Convention Center); Screen 9; In-Person Only) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1800;
By using previously obtained knowledge on fluorescent labelling and labelling conditions, and introducing lab runs to collect additional stability data, the development and clinical translation of adalimumab-680LT was strongly accelerated. The described roadmap is applicable to the development of other antibody-based fluorescent tracers as well, enabling a time reduction of months up to a year to transition from lab experiments to the production of a tracer suitable for human use.
- | Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Disease modification in axial spondyloarthritis - still a controversy? (Pubmed Central) - May 7, 2024
Moreover, changes in demographics and treatment methods underscore the importance of examining trends over time when assessing disease outcomes. Ultimately, ongoing research could benefit from new imaging tools when evaluating therapeutic strategies for modifying disease progression in axSpA.
- | Humira (adalimumab) / AbbVie
Journal: Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease. (Pubmed Central) - May 6, 2024
In patients with initial-onset VKH, adalimumab effectively reduces glucocorticoid dependence. However, adalimumab may not be effective for preventing relapse or providing long-term inflammation relief in patients with recurrent VKH.
- || Humira (adalimumab) / AbbVie
Clinical, Review, Journal: Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis. (Pubmed Central) - May 6, 2024
These agents can be ingested orally and seem superior to adalimumab for most indications...In the absence of evidence from controlled clinical trials, JAK inhibitor therapy is still rendered experimental and currently considered only for sight-threatening uveitis. JAK inhibitors may be considered for specific NIU entities for which there is insufficient response or secondary loss of response to conventional or biologic disease-modifying drugs.
- || Retrospective data, Review, Journal: Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - May 5, 2024
JAK inhibitors may be considered for specific NIU entities for which there is insufficient response or secondary loss of response to conventional or biologic disease-modifying drugs. Among all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively.
- || Clinical, Retrospective data, Review, Journal: Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis. (Pubmed Central) - May 3, 2024
Among all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively. Among patients with JIA, canakinumab exhibited the highest likelihood of being the optimal treatment for achieving the modified ACRpedi30 response rate, and neither of the tested biological agents carried a significant risk of serious adverse events.
- | Humira (adalimumab) / AbbVie
Journal: Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort?study. (Pubmed Central) - May 3, 2024
In this nationwide cohort study, the rates of GIP did not differ between groups of patients initiating JAKi and adalimumab treatment. These results need to be confirmed in other observational studies.
- | Humira (adalimumab) / AbbVie
Journal: An update on Beh (Pubmed Central) - May 2, 2024
After adalimumab received approval for the treatment of posterior ocular involvement in 2016, another agent, apremilast, became available in 2020. The drug is recommended for the treatment of recurrent oral aphthae in adult Beh
- || Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Journal: Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID p (Pubmed Central) - May 2, 2024
The drug is recommended for the treatment of recurrent oral aphthae in adult Beh IFX is effective in maintaining remission at 1 year in pediatric CD patients experiencing a LOR or intolerance with ADA, and IFX could be an interesting therapeutic choice instead of other biologics in this situation.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. (Pubmed Central) - May 2, 2024
IFX is effective in maintaining remission at 1 year in pediatric CD patients experiencing a LOR or intolerance with ADA, and IFX could be an interesting therapeutic choice instead of other biologics in this situation. No abstract available